A partially blinded, randomized trial assessing the safety and efficacy of various doses and treatment durations of combination therapies in participants with pulmonary infection of either extensively drug-resistant tuberculosis (XDR-TB), Pre-XDR-TB or treatment intolerant or non-responsive multi-drug resistant tuberculosis (MDR-TB)
Due to high patient screening and enrolment, some African sites were unable to manage kit supplies. Moreover, shipments proved challenging towards year-end and, especially, during the outbreak of the Covid-19 pandemic. The outbreak also caused strong restrictions on (international) shipping.
Discover how our team of experts rose to the occasion to help this trial succeed